5 completed, 2 active not recruiting, 1 not yet recruiting, 1 recruiting. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 5, Active not recruiting 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Hepatitis D, Chronic: new trials by email Literature Review of Hepatitis D, Chronic trials Research Report on Hepatitis D, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D Hepalatide 2.1mg, Placebo of Hepalatide - Hepatitis D, Chronic | Phase 3 | Not yet recruiting | Shanghai HEP Pharmaceutical Co., Ltd. | 150 | 2027-06-01 | 2026-10-28 |
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Brelovitug (BJT-778), Bulevirtide - Chronic Hepatitis D | Phase 2 / Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 120 | 2026-02-26 | 2026-10-27 |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 150 | 2025-07-30 | 2026-07-13 |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Tobevibart, Elebsiran - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 124 | 2025-03-12 | 2026-11-03 |
| Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection Lonafarnib, Ritonavir - Hepatitis D, Chronic | Phase 3 | Completed | Soroka University Medical Center | 10 | 2021-05-15 | 2026-04-30 |
| Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) Bulevirtide - Chronic Hepatitis Delta | Phase 3 | Completed | Gilead Sciences | 150 | 2019-04-17 | 2025-08-22 |
| A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D. peginterferon alfa-2a [Pegasys], placebo, tenofovir - Hepatitis D, Chronic | Phase 3 | Completed | Hoffmann-La Roche | 50 | 2010-02-16 | 2019-01-14 |
| Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603) Peginterferon alfa-2b (PegIntron, SCH 54031) - Hepatitis D, Chronic, Hepatitis B, Chronic | Phase 3 | Completed | Merck Sharp & Dohme LLC | 68 | 2005-12-01 | 2017-04-06 |
| A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD) Pegylated Interferon (PEG-IFN) alfa-2a - Hepatitis D, Chronic | Phase 3 | Completed | Hoffmann-La Roche | 31 | 2005-10-01 | 2016-08-26 |
Hepatitis D (4) · Hepatitis (2) · Hepatitis B (2) · Digestive System Diseases (1) · Hepatitis B, Chronic (1) · Liver Diseases (1)
Chronic Disease (9) · Disease Attributes (9) · Hepatitis, Chronic (9) · Hepatitis, Viral, Human (9) · Infections (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · RNA Virus Infections (9) · Virus Diseases (9) · Digestive System Diseases (8) · Liver Diseases (8) · Hepatitis (7) · Hepatitis D (5) · Blood-Borne Infections (2) · Communicable Diseases (2)
bulevirtide (3) · peginterferon alfa-2a (2) · Ritonavir (1) · Tenofovir (1) · lonafarnib (1) · myrcludex-B (1) · peginterferon alfa-2b (1)
Hoffmann-La Roche (2) · Vir Biotechnology, Inc. (2) · Gilead Sciences (1) · Merck Sharp & Dohme LLC (1) · Mirum Pharmaceuticals, Inc. (1) · Shanghai HEP Pharmaceutical Co., Ltd. (1) · Soroka University Medical Center (1)
Germany (4) · Romania (4) · Italy (3) · United Kingdom (3) · Austria (2) · France (2) · New Zealand (2) · Spain (2) · Turkey (Türkiye) (2) · United States (2) · Canada (1) · China (1) · Czechia (1) · Georgia (1) · Israel (1)
Junqi Niu, Professor (1) · Ohad Etzion, MD (1) · Yanhang Gao (1)
PMID 41586499, PMID 30833068, PMID 37120031, PMID 38340811, PMID 39009085, PMID 39648559, PMID 41405233, PMID 41966308
2019 (1)